Search alternatives:
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
point decrease » point increase (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
i fold » _ fold (Expand Search), 5 fold (Expand Search), 2 fold (Expand Search)
-
621
-
622
-
623
-
624
-
625
-
626
-
627
-
628
PKCε activation induces aggrecan gene expression, decreases ADAMTS5, and detection of ADAMTS-5-depended cleavage of ECM aggrecan through upregulation of hsa-miR-377 expression.
Published 2013“…<p>(<b>A</b>) RT-PCR detected the relative expression of ACAN, MKI67, ADAMTS5 after treatment of NP cells with 1 μM ψεRACK (or vehicle) for indicated times and revealed that time-dependent activation of PKCε significantly increased the mRNA expression for aggrecan, while in an opposing manner decreased ADAMTS5; mRNA levels of the proliferation marker Ki67 became barely detectable after 8 hours of PKCε activation. …”
-
629
VRK1 overexpression is seen in human breast cancer and is associated with decreased relapse-free survival.
Published 2018“…Data for cancer subtypes are shown in boxes numbered 1–11: 1: benign breast neoplasm (rank 6459, 1.4 fold-change, NS), 2: breast carcinoma (rank 833, 1.5 fold-change, p = 3.83x10<sup>-5</sup>), 3: breast phyllodes tumor (rank 512, 1.2 fold-change, p = 0.002), 4: ductal breast carcinoma in situ (rank 1969, 1.5 fold-change, p = 0.002), 5: invasive breast carcinoma (rank 1060, 1.6 fold-change, p = 1.28x10<sup>-5</sup>), 6: invasive ductal and invasive lobular breast carcinoma (rank 941, 1.5 fold-change, p = 6.76x10<sup>-22</sup>), 7: invasive ductal breast carcinoma (rank 613, 1.5-fold change, p = 2.71x10<sup>-71</sup>), 8: invasive lobular breast carcinoma (rank 947, 1.3 fold-change, p = 3.64x10<sup>-28</sup>), 9: medullary breast carcinoma (rank 400, 1.8 fold-change, p = 3.25x10<sup>-12</sup>), 10: mucinous breast carcinoma (rank 1932, 1.4 fold-change, p = 7.41x10<sup>-10</sup>) and 11: tubular breast carcinoma (rank 1253, 1.4 fold-change, p = 1.24x10<sup>-17</sup>). …”
-
630
-
631
-
632
P<i><sub>TET</sub></i>-driven OE of 20 genes results in decreased or increased growth rate. A. Impact of OE on the growth rates of 257 OE strains.
Published 2012“…Genes in orange correspond to those whose OE decreased growth with a fold equal to 2. Data are mean and SD of 3 experiments. …”
-
633
-
634
Plot of maximum power (a), amplitude (b) and frequency (c) of eel versus roughness of the cylinder.
Published 2025Subjects: -
635
-
636
-
637
-
638
-
639
Immunoblotting for insulin sensitivity markers.
Published 2024“…SIRT1 was significantly decreased in CON-I and SIT-N compared to CON-N. pPKC alpha was significantly decreased in SIT-I compared to CON-I. …”
-
640